N. gonorrhoeae, the causative agent of gonorrhea, is a gram-negative, nonmotile, non-spore-forming organism that grows singly and in pairs (i.e., as diplococci).
The ∼450,000 cases reported in the United States in 2016 probably represent only half the true number of cases because of underreporting, self-treatment, and nonspecific treatment without a laboratory diagnosis.
Except in disseminated disease, the sites of infection typically reflect areas involved in sexual contact.
Infections With Chlamydia Trachomatis
C. trachomatis organisms are obligate intracellular bacteria that are divided into two biovars: trachoma and LGV. The trachoma biovar causes ocular trachoma and urogenital infections; the LGV biovar causes LGV.
The World Health Organization (WHO) estimates that >106.4 million cases of C. trachomatis infection occur annually worldwide; it is the most prevalent of all bacterial STIs. The estimated 2-3 million cases per year that occur in the United States make C. trachomatis infection the most commonly reported infectious disease in this country.
Of pts with C. trachomatis genital infections, 80-90% of women and >50% of men lack symptoms; other pts have very mild symptoms.
TREATMENT | ||
Infections with Chlamydia Trachomatis
|
Mycoplasmas are the smallest free-living organisms known and lack a cell wall. Mycoplasma hominis, M. genitalium, Ureaplasma parvum, and U. urealyticum cause urogenital tract disease. These organisms are commonly present in the vagina of asymptomatic women.
Ureaplasmas are a common cause of Chlamydia-negative NGU. M. hominis and M. genitalium are associated with PID. M. hominis is implicated in 5-10% of cases of postpartum or postabortal fever.
TREATMENT | ||
Infections Due to MycoplasmasRecommendations for treatment of NGU and PID listed above are appropriate for genital mycoplasmas. |
Treponema pallidum subspecies pallidum-the cause of venereal syphilis-is a thin, spiral organism with a cell body surrounded by a trilaminar cytoplasmic membrane. Humans are the only natural host, and the organism cannot be cultured in vitro.
T. pallidum penetrates intact mucous membranes or microscopic abrasions and, within hours, enters lymphatics and the bloodstream to produce systemic infection and metastatic foci. After a median incubation period of ∼21 days, the primary lesion (chancre) appears at the site of inoculation, persists for 4-6 weeks, and then heals spontaneously. Generalized parenchymal, constitutional, mucosal, and cutaneous manifestations of secondary syphilis appear 6-12 weeks later despite high antibody titers, subsiding in 2-6 weeks. After a latent period, one-third of untreated pts eventually develop tertiary disease (syphilitic gummas, cardiovascular disease, neurologic disease).
Syphilis progresses through three phases with distinct clinical presentations: primary syphilis, secondary syphilis (followed by a period of latent infection), and tertiary syphilis. Syphilis can also be transmitted from mother to fetus.
Serologic tests-both lipoidal (so-called nontreponemal) and treponemal-are the mainstays of diagnosis; changes in antibody titers can also be used to monitor response to therapy.
TREATMENT | ||
Syphilis
|
Herpes Simplex Virus Genital Infections
HSV is a linear, double-strand DNA virus, with two subtypes (HSV-1 and HSV-2).
See Table 86-1 Clinical Features of Genital Ulcers for clinical details. First episodes of genital herpes due to HSV-1 and HSV-2 present similarly and can be associated with fever, headache, malaise, and myalgias. More than 80% of women with primary genital herpes have cervical or urethral involvement. Local symptoms include pain, dysuria, vaginal and urethral discharge, and tender inguinal lymphadenopathy.
HSV DNA detection by PCR is the most sensitive laboratory technique and is recommended for laboratory confirmation of HSV infection. HSV culture is indicated when antiviral sensitivity testing is required. Staining of scrapings from the base of the lesion with Wright's, Giemsa's (Tzanck preparation), or Papanicolaou's stain to detect giant cells or intranuclear inclusions is well described, but most clinicians are not skilled in these techniques, which furthermore do not differentiate between HSV and VZV.
TREATMENT | ||
HSV Genital Infections
|
H. ducreyi is the etiologic agent of chancroid, an STI characterized by genital ulceration and inguinal adenitis, and non-sexually transmitted cutaneous ulcers. In addition to being a cause of morbidity in itself, chancroid increases the efficiency of transmission of and the degree of susceptibility to HIV infection. See Table 86-1 Clinical Features of Genital Ulcers for clinical details. Culture of H. ducreyi from the lesion confirms the diagnosis; PCR is starting to become available. In the setting of a compatible clinical presentation (including one or more painful genital ulcers) and negative tests for syphilis and HSV infection, a probable diagnosis of chancroid can be made.
TREATMENT | ||
Chancroid
|
Also known as granuloma inguinale, donovanosis is caused by K. granulomatis. The infection is endemic in Papua New Guinea, parts of southern Africa, India, the Caribbean, French Guyana, Brazil, and Aboriginal communities in Australia; few cases are reported in the United States.
See Table 86-1 Clinical Features of Genital Ulcers for clinical details. Four types of lesions have been described: (1) the classic ulcerogranulomatous lesion that bleeds readily when touched; (2) a hypertrophic or verrucous ulcer with a raised irregular edge; (3) a necrotic, offensive-smelling ulcer causing tissue destruction; and (4) a sclerotic or cicatricial lesion with fibrous and scar tissue. The genitals are affected in 90% of pts and the inguinal region in 10%.
TREATMENT | ||
DonovanosisPts should be treated with azithromycin (1 g on day 1, then 500 mg qd for 7 days or 1 g weekly for 4 weeks); alternative therapy consists of a 14-day course of doxycycline (100 mg bid), trimethoprim-sulfamethoxazole (960 mg bid), erythromycin (500 mg qid), or tetracycline (500 mg qid). If any of the 14-day treatment regimens are chosen, the pt should be monitored until lesions have healed completely. |
Human Papillomavirus (Hpv) Infections
Papillomaviruses are nonenveloped, double-strand DNA viruses. More than 125 HPV types are recognized, and individual types are associated with specific clinical manifestations. For example, HPV types 16 and 18 have been most strongly associated with cervical and anal cancers, causing 70-85% and ∼90% of cases, respectively; HPV types 6 and 11 cause genital warts (condylomata acuminata).
Epidemiology and Clinical Manifestations
Most visible warts are diagnosed correctly by history and physical examination alone. The primary method used for cervical cancer screening is cytology via Pap smear every 3 years beginning at age 21; for women ≥30 years of age, the testing interval can be lengthened to 5 years if co-testing for HPV DNA is negative. Anal screening is accepted for high-risk groups.
TREATMENT | ||
Human Papillomavirus Infections
|
Prevention
A quadrivalent vaccine (Gardasil, Merck) containing HPV types 6, 11, 16, and 18; a nine-valent vaccine (Gardasil-9, Merck) containing HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and a bivalent vaccine (Cervarix, GlaxoSmithKline) containing HPV types 16 and 18 are available. The CDC recommends vaccine administration to all boys and girls at 11-12 years of age as well as to young men and women 13-26 years of age who have not previously completed the full series.
Section 7. Infectious Diseases